K. Devaraja, Sadhna Aggarwal & Manisha Singh. (2023) Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma—A Review. Vaccines 11:3, pages 634.
Crossref
Nina Blazeska, Zeynep Kosaloglu-Yalcin, Randi Vita, Bjoern Peters & Alessandro Sette. 2023. Computational Vaccine Design. Computational Vaccine Design
133
149
.
Fei Duan, June Wang, Zhaoxi Li, Tong Zhang, Zhenhua Li & Xiaohan Zhou. (2021) pH-Responsive Metal–Organic Framework-Coated Mesoporous Silica Nanoparticles for Immunotherapy. ACS Applied Nano Materials 4:12, pages 13398-13404.
Crossref
Simon Beyaert, Jean-Pascal Machiels & Sandra Schmitz. (2021) Vaccine-Based Immunotherapy for Head and Neck Cancers. Cancers 13:23, pages 6041.
Crossref
Arjelle Decasa Agupitan, Paul Neeson, Scott Williams, Jason Howitt, Sue Haupt & Ygal Haupt. (2020) P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. International Journal of Molecular Sciences 21:10, pages 3452.
Crossref
Xu Qian, Thomas K. Hoffmann, Andreas M. Kaufmann & Andreas E. Albers. 2020. Cancer Immunology. Cancer Immunology
333
354
.
Paul Zolkind & Ravindra Uppaluri. (2017) Checkpoint immunotherapy in head and neck cancers. Cancer and Metastasis Reviews 36:3, pages 475-489.
Crossref
Paul Zolkind, Gavin P. Dunn, Tianxiang Lin, Malachi Griffith, Obi L. Griffith & Ravindra Uppaluri. (2017) Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncology 71, pages 169-176.
Crossref
Demin Li, Carol Bentley, Amanda Anderson, Sarah Wiblin, Kirstie L.S. Cleary, Sofia Koustoulidou, Tasneem Hassanali, Jenna Yates, Jenny Greig, Marloes Olde Nordkamp, Iva Trenevska, Nicola Ternette, Benedikt M. Kessler, Bart Cornelissen, Mark S. Cragg & Alison H. Banham. (2017) Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy. Cancer Research 77:10, pages 2699-2711.
Crossref
Silvia von Mensdorff-Pouilly. 2017. Encyclopedia of Cancer. Encyclopedia of Cancer
3295
3302
.
Albert DeLeo & Theresa L. Whiteside. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
409
418
.
Yan Cui & Gang Guo. (2016) Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. International Journal of Molecular Sciences 17:11, pages 1942.
Crossref
Theresa L. Whiteside, Robert L. Ferris, Miroslaw Szczepanski, Mitchell Tublin, Joseph Kiss, Rita Johnson & Jonas T. Johnson. (2016) Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. Head & Neck 38:S1, pages E494-E501.
Crossref
Gang Guo & Yan Cui. (2015) New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. Journal for Immunotherapy of Cancer 3:1.
Crossref
Xu Qian, Andreas M. Kaufmann & Andreas E. Albers. 2015. Cancer Immunology. Cancer Immunology
299
311
.
Silvia von Mensdorff-Pouilly. 2016. Encyclopedia of Cancer. Encyclopedia of Cancer
1
8
.
Patrick J. Schuler, Malgorzata Harasymczuk, Carmen Visus, Albert DeLeo, Sumita Trivedi, Yu Lei, Athanassios Argiris, William Gooding, Lisa H. Butterfield, Theresa L. Whiteside & Robert L. Ferris. (2014) Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer. Clinical Cancer Research 20:9, pages 2433-2444.
Crossref
Albert DeLeo & Theresa L Whiteside. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
10
.
Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Jeffrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside & Samir N. Khleif. (2011) A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy 61:3, pages 373-384.
Crossref
Özcan Met, Eva Balslev, Henrik Flyger & Inge Marie Svane. (2010) High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Research and Treatment 125:2, pages 395-406.
Crossref
Silvia von Mensdorff-Pouilly. 2011. Encyclopedia of Cancer. Encyclopedia of Cancer
2698
2704
.
A. E. Albers, L. Strauss, T. Liao, T. K. Hoffmann & A. M. Kaufmann. (2010) T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer. Clinical and Developmental Immunology 2010, pages 1-14.
Crossref
Anne S.De Groot, Tobias Cohen, Matthew Ardito, Lenny Moise, Bill Martin & Jay A. Berzofsky. 2010. Immunology of Infection. Immunology of Infection
35
66
.
Ronald C. Hendrickson, Vito R. Cicinnati, Andreas Albers, Grzegorz Dworacki, Andrea Gambotto, Ornella Pagliano, Thomas Tüting, Jose I. Mayordomo, Carmen Visus, Ettore Appella, Jeffrey Shabanowitz, Donald F. Hunt & Albert B. DeLeo. (2009) Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide. Cancer Immunology, Immunotherapy 59:1.
Crossref
Tobias Cohen, Lenny Moise, William Martin & Anne S. De Groot. 2010. Infectious Disease Informatics. Infectious Disease Informatics
223
244
.
Geke A.P. Hospers, Coby Meijer, Wendy A. Dam, Frank Roossink & Nanno H. Mulder. (2009) Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen. Vaccine 28:2, pages 386-391.
Crossref